Corporation
Eli Lilly Canada Inc.
- Meetings this Parliament
- 21
- With MPs
- 6
- Since Nov 2021
- 65
- Active registrations
- 1
Most recent reported meeting: Sep 25, 2026.
Lobbying by Eli Lilly Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Sep 1, 2026
Filed by Mathilde Merlet, President and General Manager
Lobbyists
- Jill Daley · General Counsel & Vice-President Corporate Affairs
- Mathilde Merlet · President and General Manager
Institutions they may lobby: Federal Economic Development Agency for Southern Ontario (FedDev), Finance Canada (FIN), Global Affairs Canada (GAC), Great Lakes Pilotage Authority, Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Invest in Canada Hub, Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (10)Hide details
- C-64, An act respecting pharmacare - discussions around the structuring and implementation of a national pharmacare program.
- The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
- Pharmaceutical pricing policy arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
- Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines.
- Patented Medicines Pricing Review Board (PMPRB) – regulations that can impact the Canadian pharmaceutical industry.
- Patented Medicine Notice of Compliance (PMNOC) Regulations - enforcement of Intellectual Property with respect to the Canadian pharmaceutical industry.
- Patent Act - An Act respecting patents of invention with regard to Intellectual Property Protection for pharmaceutical products - federal court decisions that have changed the disclosure requirements regarding the utility of an invention.
- Intellectual Property - Changes to Patented Medicine (Notice of Compliance) (PMNOC) regulations - important regulations that can affect Eli Lilly Canada's business
- Free trade treaty agreement as it relates to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to Columbia, India, and the European Union
- Food and Drug Act - An Act respecting food, drugs, cosmetics and therapeutic devices. Discussions relating to progressive licensing and the modernization of the Food and Drug Act.
Registration 960985-6034-39. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Kenneth L Custer (25), Mathilde Merlet (21), Rhonda Pacheco (19).
-
Reported by Mathilde Merlet · In-house (corporation)
- Eric Costen · Deputy Secretary to the Cabinet (Operations), Privy Council Office (PCO)
Pharmaceutical pricing policy arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Read more
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines.
-
Reported by Mathilde Merlet · In-house (corporation)
- Paul Moen · Chief of Staff, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Mathilde Merlet · In-house (corporation)
- Samuel Millar · Assistant Deputy Minister, Finance Canada (FIN)
- Omar Rajabali · Director General, Finance Canada (FIN)
- Nicholas Chesterley · Director General, Finance Canada (FIN)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Mathilde Merlet · In-house (corporation)
- Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Mathilde Merlet · In-house (corporation)
- Karim Bardeesy · Member of Parliament
- Paul Moen · Chief of Staff to the Minister, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Philip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Mathilde Merlet · In-house (corporation)
- Alexis Conrad · Assistant Secretary to the Cabinet, Economic Regional Development Policy, Privy Council Office (PCO)
- Isabelle Mondou · Deputy Clerk of the Privy Council and Associate Secretary to the Cabinet, Privy Council Office (PCO)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Mathilde Merlet · In-house (corporation)
- Maggie Chi · Member of Parliament
- Justine Frame · Policy Advisor, Health Canada (HC)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Mathilde Merlet · In-house (corporation)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Mathilde Merlet · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Karim Bardeesy · Member of Parliament
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Janice Charette · Chief Trade Negotiator, Global Affairs Canada (GAC)
and 7 moreShow fewer
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Martin Moen · Associate Assistant Deputy Minister for International Trade, Global Affairs Canada (GAC)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Policy Advisor, Health Canada (HC)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Mathilde Merlet · In-house (corporation)
- Martin Moen · Associate Assistant Deputy Minister for International Trade, Global Affairs Canada (GAC)
- Loris Mirella · Director, Global Affairs Canada (GAC)
- Patrick Blanar · Director, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
and 1 moreShow fewer
- David Noris · Senior Trade Policy Officer, Global Affairs Canada (GAC)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Mathilde Merlet · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Mathilde Merlet · In-house (corporation)
- Miro Froehlich · Director of Policy, Privy Council Office (PCO)
- Brandan Rowe · Chief of Staff, Privy Council Office (PCO)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Mathilde Merlet · In-house (corporation)
- Brandan Rowe · Chief of Staff, Privy Council Office (PCO)
- Miro Froehlich · Director of Policy, Privy Council Office (PCO)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Mathilde Merlet · In-house (corporation)
- Brandan Rowe · Chief of Staff, Intergovernmental Affairs Secretariat (IGA)
- Miro Froehlich · Director of Policy, Intergovernmental Affairs Secretariat (IGA)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Mathilde Merlet · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
- Daniel MacDonald · Director General, Health Canada (HC)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Mathilde Merlet · In-house (corporation)
- Mélanie Joly · Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Mathilde Merlet · In-house (corporation)
- Andrea Clements · Sr Trade Commissioner, Global Affairs Canada (GAC)
- Kaitlyn Pritchard · Trade Program Manager, Global Affairs Canada (GAC)
- Wallace Ip · First Secretary (defence trade policy), Global Affairs Canada (GAC)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry Read more
Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines.
-
Reported by Mathilde Merlet · In-house (corporation)
- Matt Strauss · Member of Parliament
- Sean Finnigan · Chief of Staff, House of Commons
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry Read more
Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines.
-
Reported by Mathilde Merlet · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry Read more
Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines.
-
Reported by Mathilde Merlet · In-house (corporation)
- Daryl Fridhandler · Senator, Senate of Canada
Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines. Read more
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Mathilde Merlet · In-house (corporation)
- Peter Fragiskatos · Member of Parliament
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry Read more
Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines.
-
Reported by Kenneth L Custer · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Kenneth L Custer · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Philip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Kenneth L Custer · In-house (corporation)
- Shuvaloy Majumdar · Member of Parliament
Health
-
Reported by Kenneth L Custer · In-house (corporation)
- Mohamed-Iqbal Ravalia · Senator, Senate of Canada
Health
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.